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Background: Oral and pharyngeal cancer (OPC) of multifactorial aetiology is a major health problem globally.
Ranking first in all cancers, OPC poses a significant impact on the Sri Lankan male population. As Human
Papillomavirus (HPV) high risk (HR) types are found to be significant risk factors for OPC globally, the current study
was undertaken to examine the association between HR-HPV16 and 18 types with OPC in Sri Lanka.
Materials and methods: Serum samples of 78 OPC patients and 51 non-cancer controls were assayed for the
presence of anti-HPV16 and anti-HPV18 IgG antibodies using in-house established Enzyme Linked Immunosorbent
Assays (ELISAs). The association between OPC and its risk factors i.e. HPV, smoking, alcohol, betel quid, poor
dentition, was established using Chi-square test. Logistic regression was used to calculate odds ratios (OR),
adjusted for the influence of other risk factors.
Results: This prototype study in Sri Lanka showed a significant risk of 15 fold in developing OPC due to HPV16/18
seropositivity after removing variability due to other factors. Oncogenic HPV18 showed a higher rate of
seropositivity being detected in 32% of OPC patients, and also in 2% of non-cancer control subjects. HR-HPV16 was
detected in 23% of OPC patients and in 5.88% of controls. Moreover, seven OPC patients were detected with both
anti-HPV16 and anti-HPV18 antibodies. According to the logistic regression models HPV18 seropositivity was
associated with a 28 fold risk in developing OPC while that of HPV16 was associated with a 6 fold increase in risk
for the development of OPC. A 5 fold risk of developing OPC was also pronounced among smokers while alcohol,
betel and poor dentition was not significantly associated with OPC. Statistically significant differences with regard to
age, gender, smoking, alcohol, betel use, poor dentition and site specificity of the tumour was not observed
between HPV seropositive and seronegative OPC patients.
Conclusions: Both in-house developed ELISAs detected significant proportions of HPV seropositives within the OPC
study population suggestive of HPV as a strong risk factor for oral and pharyngeal carcinogenesis in Sri Lanka.
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Oral and pharyngeal cancer (OPC) is a significant com-
ponent of the global burden of cancer, worldwide being
the sixth most common cancer and the eighth most
common cause of cancer death [1,2]. Sri Lanka is a high
risk region for the disease with high incidence rates glo-
bally [3]. Also, collectively lip, oral cavity and pharyngeal
cancer rank first in cancer incidence in the male popula-
tion of Sri Lanka (Cumulative rate 1.906) with increasing
age specific rates [4].
Several epidemiologic investigations carried out glo-
bally documented the correlation between consumption
of tobacco, alcohol, and betel chewing as major risk fac-
tors for developing OPC with a dose-response relation-
ship [5-7].
In developing countries up to 23% of malignancies are
caused by infectious agents, including HPV [1]. HPV, in
addition for being a successful sexually transmitted infec-
tious agent associated with anogenital warts and mild dys-
plasia [8] has cell-immortalizing and cell-transforming
properties [9] which mediate oncogenesis. The high-risk
human papillomavirus (HR-HPV) types are well con-
firmed as aetiologic agents of cervical cancer [10,11].
Compelling studies carried out worldwide provide suffi-
cient evidence that infection with HR-HPV can be impli-
cated in the pathogenesis of OPC [12-15].
Presence of HPV DNA in a sample population of Sri
Lankan patients with oral squamous cell carcinoma was
previously reported. The positivity was detected by PCR
and direct cycle sequencing and the highest HPV positivity
was found in the buccal mucosa. The overall HPV preva-
lence of the study sample was 37.2% (N = 102) [16]. Thus,
apart from betel quid the study suggested that HPV is a
strong risk factor for oral carcinogenesis in Sri Lanka.
The current study examined the associations between
established risk factors of OPC, with special emphasis
on HPV as a suspected major emerging risk factor deter-
mining oral and especially pharyngeal cancer in Sri
Lanka. Sero-prevalence of HPV was detected with in-
house developed indirect enzyme-linked immunosorbent
assays (ELISAs) specific for HPV16 and HPV18, using
virus-like particles (VLPs) produced for the L1 region of
the HPV genome.
Results
Study subjects: Socio-demographic factors and medical
information
Cases (N = 78) and controls (51) were comparable with
regard to age and gender (P > 0.05). Males (94%) were
more likely than females (6%) to be diagnosed with
OPC. Age of cases ranged from 38 to 77 years. A higher
proportion of the patients (66.7%) had only received pri-
mary education. From the 25 districts in Sri Lanka, resi-
dency of the cases covered ten.Among the cases, 33 (42%) had cancers of the oral
cavity while 45 (58%) had pharyngeal cancers with sub
sites including floor of the mouth, hard palate, tongue,
retro molar buccal mucosa, soft palate, tonsil, cheek,
maxilla antrum and oropharynx. Patients were not diag-
nosed for any other carcinomas previously with the ex-
ception of one case with a cancer in the sigmoid colon,
and a majority (86%) had no family history of cancer.Anti-HPV IgG detection and HPV as a risk factor for OPC
Serologic response, i.e. anti-HPV16/18 IgG antibodies, of
the case and control subjects is shown in Figure 1. The
cut-off values for HPV16 L1 and HPV18 L1 indirect
ELISAs estimated after the exclusion of outliers in the
control group were 0.262 and 0.1777, respectively (Figure 1).
The mean OD values for anti-HPV IgG response of the
case group were significantly higher than that of the control
group for both HPV16 and HPV18 VLPs (HPV18: P = 0.00;
HPV16: P = 0.035).
Seropositivity to HPV18 L1 VLP was significantly dif-
ferent between cases (32%) and controls (1.96%). The se-
ropositives pose a momentous 24-fold increase in risk
for OPC when compared with seronegatives (OR =
23.57; 95% CI: 3.08-180.62). Although, the wide confi-
dence interval indicates an imprecise estimate due to the
small sample size, the magnitude of risk estimate sug-
gests a strong positive association between seropositivity
to HPV18 and OPC. A significant difference (P = 0.019)
was also detected in the seropositivity of HPV16 cases
(18/78; 23.1%) compared with the controls (3/51; 5.8%),
but with only a 4.8-fold risk in developing OPC with ref-
erence to the seronegatives (OR = 4.8; 95%CI, 1.335-
17.261). OPC patients seropositive for either HPV16 or
HPV18 comprised 46% of the cases with a significant dif-
ference with the seropositivity of the control group (P =
0.00), and with a 13.71-fold risk of developing OPC with
contrast to seronegatives (Table 1). Seven cases were co-
infected with HPV16 and HPV18.
Results of each indirect ELISA revealed 3 groups for
anti-HPV IgG positivity (Figure 2). Based on the as-
sumption that the OD value is directly proportional to
the antibody magnitude and hence to the viral load, the
groups can be defined as being low, moderate and high.
In addition, cases detected with ‘high’ and ‘moderate’
anti-HPV antibody magnitudes had stage IV tumours.
Besides, seropositive individuals for anti-HPV16 anti-
bodies showed higher OD415 values (ranging from 0.26
to 2.1) than those with anti HPV18 antibodies (0.177 to
0.536), indicative of a higher antibody response for
HPV16 compared with HPV18. This was reiterated for
OPC patients with co-infections of HPV16 and HPV18,
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Figure 1 Anti-HPV IgG responses in OPC patients and non-cancer controls in a Sri Lankan population. (A) Anti-HPV18L1 and (B) Anti-HPV16L1
IgG responses of the case and control groups. Each enclosed circle represents the mean of duplicate OD values at 415 nm, of each serum sample.
Long horizontal lines represent the cut-off values (the mean OD value at 415 nm plus 2 standard deviations of the control group excluding
outliers) and the short horizontal lines represent the mean values for HPV18L1 and HPV16L1 ELISA. Mean OD values obtained for test samples
falling over and above this cut-off level were expressed as positive responses.
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cancer
The association of OPC with smoking, alcohol, betel
quid chewing and poor dentition is shown in Table 2.
Poor dentition (manifested as tooth loss) was excluded
as a significant risk factor for OPC in this study as there
was no significant difference (P = 0.213) observed be-
tween cases and controls (Table 2). Among the smokers,
50% (39/78) were light smokers (<10 cigarettes/day),
20.5% (16/78) were moderate smokers (10-20 cigarettes/
day) while 11.5% (9/78) were heavy smokers (>20 ciga-
rettes/day). Comparing smoking intensity with the num-
ber of years smoked, 82.5% (52/63) of the smokers had
been exposed to tobacco for more than 20 years and in
25.4% (16/63) the usage time exceeded 40 years. Of the
heavy smokers the majority had a usage time period of
15-30 years while only 1 case was a smoker for 50 years.Aetiology of OPC with independent risk assessment
Influence of each risk factor for the development of
OPC after adjusting for the influence of other significantTable 1 Association of OPC with prevalence of anti-HPV IgG a
Characteristic OPC cases (N = 78) Controls (N =
HPV16/18 L1 serologic status
Seronegative 42 (53.8%) 48 (94.12%)
Seropositive 36 (46%) 3 (5.88)
HPV16L1 serologic status
Seronegative 60 (76.9%) 48 (94.1%)
Seropositive 18 (23.1%) 3 (5.8%)
HPV18 L1 serologic status
Seronegative 53 (68%) 50 (98.04%)
Seropositive 25 (32%) 1 (1.96%)risk factors using binary logistic regression models is
shown in Table 3.
In the first model, after accounting for other factors
(smoking, alcohol consumption and betel quid chewing)
cases being seropositive for HPV16 was statistically sig-
nificant with reference to the control subjects (P = 0.012)
with a risk of 5.89-fold. A case subject being seropositive
for HPV18 was statistically significant with reference to
the control subjects (P = 0.003) after adjusting for smok-
ing, alcohol consumption and betel quid chewing. The
seropositives showed a marked increase of a 28-fold risk
in developing OPC compared with the seronegatives
(OR = 28.29) (model 2). The adjusted OR for both
HPV16 and HPV18 was higher than the unadjusted OR
suggesting that HPV16 and HPV18 unaided act as an
important risk factor for OPC which can drive an onco-
genic effect notwithstanding other risk factors. As per
the third logistic regression model only HPV18 and
smoking posed significant risks. Individuals seropositive
for HPV18 were associated with a 20-fold risk of devel-
oping OPC after removing influence due to other fac-
tors. Smoking accounted for risk of 4.92 fold. Those whontibodies in a Sri Lankan study population
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Figure 2 Type-specific distribution of anti-HPVL1 IgG magnitudes of the HPV seropositive oral and pharyngeal cancer patients. (A) HPV18 L1 and
(B) HPV16 L1. Each circle represents a single sample. Anti-HPV18L1 IgG magnitudes: Low (OD415< 0.3), Moderate (0.3 < OD415< 0.5), High (OD415> 0.5).
Anti-HPV16L1 IgG magnitudes: Low (OD415< 1.0), Moderate (1.0 < OD415< 2.0), High (OD415> 2.0).
Gunasekera et al. Infectious Agents and Cancer  (2015) 10:12 Page 4 of 9were seropositive with either high-risk HPV16 L1 or
HPV18 L1 or both, showed a 15-fold risk of developing
OPC relative to seronegative subjects for the two HPV
types after controlling for other risk factors (model 4).
Accordingly, smoking was also found to be significant
(P = 0.004) with a 4.67-fold risk factor. Alcohol use and
betel quid chewing were not statistically significant (P >
0.05) risk factors in developing OPC when exposure to
HPV18 and/or HPV16 was present. Conversely, smoking
was a significant risk factor in all models developed even
after adjusting for HPV seropositivity.
None of the established risk factors such as smoking,
alcohol use, betel quid chewing, poor dentition nor age
and gender (data not shown), were significantly different
(P > 0.05) between the HPV16/18 seropositive and sero-
negative OPC patients.Table 2 Association of OPC with well-established risk factors:
Characteristic OPC cases (N = 78) Controls (N =
Smoking
Smokers 63 (80.8%) 23 (45.1%)
Non-smokers 15 (19.2%) 28 (54.9%)
Alcohol
Users 70 (89.7%) 37 (72.5%)
Non-users 8 (10.3%) 14(27.5%)
Betel
Users 51 (65.4%) 21 (41.2%)
Non-users 27 (34.6%) 30 (58.8%)
Poor dentition
Tooth loss 54 (69.2%) 29 (56.8%)
No loss 24 (30.8%) 22 (43.1%)HPV seropositivity and associated factors
Of the OPC patients HPV seropositivity was detected in
individuals ranging in age from 41-72 years of which a ma-
jority (38.8%) was within the 50-59 age group (Figure 3).
HPV seropositivity of the 40-49 and the 60-69 groups were
similar (25%) with a decline thereafter. Male predomin-
ance was observed with HPV seropositive OPC patients at
a ratio of 17:1.
Seropositivity of HPV was higher among light smokers
(41.6%) and non-smokers (25%). Notably three of the
seven patients co-infected with HPV16 and 18 types were
non-smokers. The anti-HPV antibody magnitudes of these
three cases were ‘high’ for HPV16 while high antibody
magnitude for HPV18 was detected in a single patient.
Patients with cancers of both the oral cavity and the
pharynx were detected with anti-HPV16L1/18 L1 IgGsmoking, alcohol, betel and poor dentition









Table 3 Risk of developing OPC due to established and emerging aetiological factors in Sri Lanka
Risk factor Model 1a Model 2b Model 3c Model 4d
P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI)
HPV 18 _ _ 0.002 28.29 (3.444-232.412) 0.005 20.78 (2.56-168.80) 0.00 15.15 (3.933-58.346)
HPV16 0.012 5.89 (1.466-23.676) _ _ 0.088 3.49 (0.829-14.683)
Smoking 0.001 4.65 (1.805-11.957) 0.002 4.94 (1.769-13.809) 0.003 4.92(1.732-13.95) 0.004 4.67(1.658-13.161)
Alcohol use 0.645 1.33 (0.395-4.475) 0.734 1.26(0.326-4.904) 0.622 1.42(0.354-5.67) 0.525 1.56(0.399-6.075)
Betel quid use 0.114 1.92(0.855-4.306) 0.127 1.95(0.827-4.576) 0.204 1.76(0.735-4.222) 0.320 1.56(0.650-3.737)
aModel 1 Adjusted for HPV16, smoking, alcohol and betel.
bModel 2 Adjusted for HPV18, smoking, alcohol and betel.
cModel 3 Adjusted for HPV18, HPV16, smoking, alcohol and betel.
dModel 4 Adjusted for HPV16/18, smoking, alcohol and betel.
Table 4 Association of tumour characteristics with HPV






Tumour site (N = 78)
Oral cavity 20 13 0.633 0.426
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bodies were detected in patients with pharyngeal than
those with oral cancer. None of the tumour characteris-
tics (tumour grade, size, stage and nodal involvement)
showed a significant difference (P > 0.05) with the HPV
serologic status (Table 4). Remarkably, 27.8% of HPV sero-
positives were diagnosed with cancers of the tonsils. Of
the seven OPC patients co-infected with HPV16 and
HPV18, 4 were oral cancer patients and 3 were diagnosed
with pharyngeal cancer. Three patients did not show any
nodular involvement and all 7 cases were at an advanced
tumour stage (Stage III:2; Stage IV:5). The tumour grade
of all 7 cases were either moderately or well differentiated.
Influence of other risk factors and histopathologic charac-
teristics on the dual exposure could not be assessed statis-
tically due to the small sample size.
Discussion
Sri Lanka is facing a precarious health problem with oral
and pharyngeal cancer (OPC) having the highest age
standardized rate per 100,000 populations (ASR/P: 15.5)
for oral cancer in Asia and ranking 3rd in the world. For
pharyngeal cancers Sri Lanka ranks 4th in Asia and 11th
in the world with an ASR/P of 7.2. Notably, both exceed
























Figure 3 Age distribution of HR-HPV16 and/or HR-HPV18 seropositivity,
in 36 oral and pharyngeal cancer patients from Sri Lanka.There is sufficient evidence for a causal role of to-
bacco, alcohol, betel quid chewing and poor oral hy-
giene with OPC in Sri Lanka [17-20], but lacked
association with HPV. Albeit, prevalence of HR-HPV in fe-
males diagnosed with cervical cancer has been studied [21],
reports on HPV burden on men and OPC is scarce. How-
ever, a study investigated HPV in oral but not pharyngeal
cancers in Sri Lanka [16]. Therefore, detection of anti-HR-
HPV antibodies in patients of pharyngeal cancer in the
present study provides novel insights to the risks of OPC in
Sri Lanka.
The infection with HR-HPV typically lasts from 12-18
months and is eventually cleared by the immune system
[22]. Compared with HPV infections that clear, persist-
ent HR-HPV infections have a higher chance of progres-
sing in to malignancy [23] that usually takes a course ofPharynx 22 23
Tumour grade (N = 55)
Poor/undifferentiated 1 1
Well/moderate 26 27 0.00 1.00
Tumour size (N = 61)
T0-T2 12 17
T3-T4 16 16 0.174 0.676
Nodal involvement (N = 61)
Yes 24 25
No 4 8 0.425 0.515
Stage (N = 60)
I/II 2 4
III/IV 25 29 0.03 0.863
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that the presence of anti-HPV antibodies are correlated
with oral and pharyngeal tumors that were positive for
HPV DNA compared to HPV DNA negative tumors
[25-27]. The current study substantiated the association
of HPV16 and HPV18 with the aetiology of OPC in Sri
Lanka, evidenced by the detection of anti-HPV16 and
anti-HPV18 IgG antibodies detected by in-house devel-
oped ELISAs.
Global prevalence and type distribution of HPV in
OPC remains unclear [28]. The striking 28-fold risk ob-
tained from model 2 (Table 3) evidenced that HPV18
may be a major risk factor for the development of OPC
in Sri Lanka. Furthermore, the high magnitude of the
OR for HPV18 seropositivity increased after controlling
for the confounding effect of smoking, alcohol and betel
chewing indicating HPV18 as an independent risk factor
for OPC. These results agree with a study investigating
HPV in oral squamous cell carcinoma in a Brazilian
population where they found HPV18 as the most preva-
lent HPV type in their study population [29]. Conversely,
in the present study, HPV16 posed only a 4.8-fold risk
of developing OPC which increased after adjustment for
smoking, alcohol and betel chewing.
Nonetheless, this indicates a paradox with most of the
prevailing records on HPV related OPC. A multicenter
study conducted in nine countries evidenced that
HPV16 unaided accounted for more than 90% of HPV-
positive OPC, and that HPV18 was less of an important
risk factor as this was detected infrequently in OPC pa-
tients [12]. However, studies conducted in Taiwan re-
vealed that HPV16 and HPV18 had co-dominant roles
in the aetiology of oral carcinogenesis [30,31].
The risk of malignancy and differential response to-
wards OPC in individuals who are exposed to more than
one type of HR-HPV is still unclear [32]. However, ap-
proximately 20% of HPV infected OPC patients in the
current study were detected with both anti-HPV16 and
anti-HPV18 antibodies. Influence of other risk factors
and histopathologic characteristics on the dual exposure
could not be assessed statistically due to the small sam-
ple size of the study. Nevertheless, it can be concluded
that HPV16 and HPV18, independently or in synergy
are associated with risk of carcinogenesis in the oral and
pharyngeal region.
The aetiology of an infectious disease is dependent on
the agent, host and environment [33]. However, viral
oncoproteins of HR-HPV types are implicated as the
drivers of transformation in HPV related OPC and evi-
dence suggests that HR-HPV strains may initiate oral
carcinogenesis among abstainers of alcohol and tobacco
[34,35]. Thus, investigating the life style factors associ-
ated with OPC patients are important in drawing suppo-
sitions for the involvement of HPV in OPC. Smokingwas confirmed as a strong risk factor for OPC. More-
over, the decrease in the association after adjustment for
other risk factors (alcohol, betel and HPV16/18) was
negligible denoting that smoking contributes substantial
independent risk prediction. Alcohol consumption is
found to be associated with increased risk for OPC, with
dose-response relationships observed [36-38]. Betel
chewing is a major risk factor for the development of
OPC especially in the Asian region [39]. In a study con-
ducted in Sri Lanka, 64% of oral cancer patients were
habitual betel chewers [16]. Betel chewing is still prac-
ticed in both rural and urban areas of the island with
new forms (‘beeda’) being introduced [20]. Conversely,
the current study excluded the significance of both alco-
hol consumption and betel quid chewing as risk factors
for OPC in the presence of HPV16/HPV18 infection.
That HPV-seropositive OPC was not significantly asso-
ciated with age of the patient in the current study, contra-
dicts the postulate that younger age groups (30-50 years)
are at a higher risk of developing OPC due to HPV [40].
Since infection with HPV is likely an early oncogenic
event in OPC, the rise of HPV seropositives in the age
group of 50-59 years may be an indicator for the infection
occurring in the 4th decade of their life. The Sri Lankan
situation may be different from that of other geographical
regions having middle aged men more inclined to the risk,
though the small sample size of the present study may
pose a limitation on drawing presumptions.
Studies indicate that HPV plays a definite aetiologic
role in cancers of the oropharynx and in a small group
of cancers of the oral cavity [12,15]. The current study
showed no significant difference in HPV16/18 seroposi-
tivity for cancers in the oral cavity and the pharynx.
Though not significant (P > 0.05) probably due to the
small sample size, a 4 fold increased risk with alcohol
and 2 fold increased risk with HPV18 seropositivity and
smoking was associated with pharyngeal cancer.
In general, at the base-line, tumor stage III/IV, poorly
differentiated tumor grade and N2-3 nodal involvement
show significantly increased risk in detecting anti-HPV
antibodies [41]. Due to lack of awareness and education,
early stages of OPC are not detected among Sri Lankan
patients at the time of diagnosis. Thus, such correlations
could not be inferred from the current study.
The increasing prevalence rate of HPV in OPC high-
lights the change of life style in sexual behavior. The
route of HPV infection in the oral and pharyngeal region
is not firmly established [27]. However, epidemiologic
evidence suggests sexual transmission, though direct
mouth-to-mouth contact or other means are not ruled
out [13]. Social and cultural barriers in Sri Lanka, failed
the effort of investigating the mechanism of transmission
of the virus by assessing the sexual history of the partici-
pants in this study.
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of OPC in Sri Lanka: Low risk HPV positive tumors aris-
ing in non-smokers; moderate risk HPV positive tumors
arising in former or current smokers; high risk HPV-
negative tumors arising in current or former smokers;
and the fourth category being HPV negative tumors aris-
ing in non-smokers. The fourth category may include
heavy alcohol use, habit of betel chewing or any other
variant associated with OPC.
A major limitation of this research is the case-control
design of the study which precludes establishment of a
causal link between HR-HPV and OPC. As serological
response to HPV is a surrogate marker of both current
and past infection, it does not indicate whether infection
was acquired prior to the development of OPC. An OPC
patient could have acquired HPV infection few months
prior to being diagnosed with OPC and hence had posi-
tive serology at the study enrollment, wherein HPV
would not be ‘causally’ associated with OPC. Hence, a
prospective longitudinal study should be undertaken to
establish causal relationship between HPV and OPC.
Interestingly, HPV positive tumors respond well to
treatment showing a potential benefit of a more favor-
able outcome from therapy compared to HPV negative
OPC [42]. Thereby, the variation in response to therapy
has been of consideration for de-escalation of treatment
intensity for these tumors [43] and retrospective data
show that HPV positive OPC are readily cured using
radiotherapy alone [44]. Thus, HPV status of the OPC
patient at diagnosis can be a predicting factor in deter-
mining the course of treatment. Since, 22% of HPV posi-
tive cases were non-smokers, the outcome of the current
study may be an incentive for prospective epidemiologic
studies using larger sample sizes to change the face of
therapy in OPC in Sri Lanka. De-escalation of therapy
will reduce the morbidity of patients and importantly
will be less costly, that would benefit a developing coun-
try such as Sri Lanka that provides free healthcare ser-
vice to the public. Knowledge on HPV serologic status
may also be a predicting variable for the development of
OPC in asymptomatic individuals where early treatment
measures can be implicated. Future investigations in-
volving molecular evidence i.e analysis of HPV DNA in
formalin fixed paraffin embedded cancer tissues and ex-
pression of its oncogenic genes E6 and E7, to support the
role of HPV in the pathogenesis of oral and pharyngeal
cancer, and epidemiologic evidence that will guide HPV
related oral and pharyngeal cancer control and prevention
programmes in Sri Lanka will be of great importance in
the local and global scale.
Conclusions
This study was the first to follow established major risk
factors with HR-HPV in both oral and pharyngealcarcinoma in Sri Lanka. Two in-house established ELISAs
detected anti-HPV16 and anti-HPV18 IgG antibodies. The
results showed a plausible association between HR-HPV
and OPC with 46% of the case group being seropositive
for HPV16/18; HPV18 and HPV16 were detected in 32%
of the patients with a risk of 28 fold and in 23% with a 6
fold risk confounding other risk factors, respectively.




The case-control study received approval of the Ethics
Review Committee, Faculty of Medicine, University of
Colombo (EC12/29), Sri Lanka.
Study subjects and data collection
Clinically diagnosed OPC cases were recruited from the
National Cancer Institute, Sri Lanka between April-
September 2012. Newly enrolled patients and those who
received a single dose of chemotherapy or radiotherapy
for OPC were the inclusion criteria. Exclusion criteria
were severely ill patients and individuals who declined
to participate. Written, informed consent was obtained
prior to the interview and sample collection. Patients
were interviewed using an approved questionnaire to ac-
crue information on socio-demographics, use of tobacco,
alcohol and betel, oral hygiene and sexual practices.
Medical information of the patients was retrieved from
their clinical records. Comparable to the enrolled cases
(N = 78), 51 age and gender matched healthy individuals
with no personal history of cancer were recruited as
controls to the study.
Variables on smoking history were ascertained by gen-
eral discussion that assessed the number of cigarettes
smoked per day, age at which an individual started to
smoke, the number of years smoking was practiced and
number of years since quitting. Similar information was
obtained regarding lifetime consumption of alcohol and
betel quid.
A supplemental question included in the question-
naire, which inquired on sexual practices, was not prag-
matic due to social and cultural barriers in Sri Lanka.
Collection of serum samples
A sample of blood (1 ml) was aseptically collected from
the study subjects via intravenous bleeding. Separated
serum samples were stored at -20°C until further use [45].
Anti-HPV IgG detection using Indirect Enzyme-linked
Immunosorbent Assay
IgG antibodies against HPV-specific proteins were
assayed using two in-house established indirect enzyme-
linked immunosorbent assays (ELISA).
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18 expressing L1 protein and H16.V5 and H18.J4 type-
specific monoclonal antibodies [46] were used to deter-
mine optimal antigen concentrations. Reagents and
buffers were optimized using checker board titrations.
Wells of microtiter plates (Immulon2, Germany) were
coated with 100 μl of VLPs (HPV16 VLP: 4.6 μg/ml,
HPV18 VLP: 4 μg/ml) in PBS (pH 7.4) and incubated
overnight at 4°C. All subsequent incubation steps in-
volved 37°C for 1 hour. Non-specific binding sites were
blocked with milk buffer (5% w/v non-fat milk powder
in PBS) and the plate was flick-washed with washing
buffer (0.5% Tween20 in PBS). Human serum diluted in
dilution buffer (5% w/v non-fat milk powder in washing
buffer) at 1:100 was added to duplicate wells and follow-
ing incubation, unbound reagents were removed by
flick-washing. The bound antibodies were detected with
alkaline phosphatase linked anti-human IgG antibody
(Sigma chemicals, USA) and the reaction was visualized
by the addition of PNPP (HIMEDIA, India). The reaction
was arrested with 3 M NaOH and the optical density
(OD) was measured at 415 nm in an automated ELISA
plate reader (Model 680, BioRad International, USA).
The negative control method [47] was used to deter-
mine the cut-off value (COV) for the HPV seropositivity.
The outliers of the control group were excluded when
setting the cut-off values. The COVs for the two ELISAs
were derived by using the mean OD value of the nega-
tive controls plus 2 times the standard deviation.
Statistical analyses
Statistical analyses were performed using SPSS version
16 for Windows (SPSS Inc, USA) software package.
Comparisons of normally distributed variables of inde-
pendent samples were performed using the t-test. When
variable distribution was not normalized, the Mann-
Whitney U test was used to compare variables between
groups. The Chi-square test was used to compare cat-
egorical variables between groups (e.g. cases vs. controls,
seropositive cases vs. seronegative cases). Binary logistic
regression was used to model the relationships between
presence of OPC and its predictor variables. Calculated
odds ratio (OR) measured the risk of developing OPC.
Wald statistic was used to determine parameter signifi-
cance (P-value) in logistic regression analyses. The level
of significance was set at P < 0.05.
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